Table 2.
Post-dosimetric parameters
| Naftopidil (n=70) | Silodosin (n=71) | p-value | |
|---|---|---|---|
| Median (range) | Median (range) | (Mann–Whitney U test) | |
| PV (mL) at postdosimetry | 26.8 (13.8-47.0) | 29.1 (12.4-54.5) | 0.031 |
| %D90 (%) | 114.1 (91.8-144.5) | 115.5 (90.1-138.8) | 0.410 |
| D90 (Gy) | 169.0 (110.6-213.5) | 169.8 (115.9-218.5) | 0.638 |
| V100 (%) | 95.8 (80.2-99.5) | 96.0 (83.1-99.6) | 0.378 |
| V150 (%) | 60.9 (33.6-87.9) | 60.6 (32.5-84.4) | 0.800 |
| UD30 (Gy) | 204.0 (123.7-267.4) | 198.6 (133.0-276.6) | 0.939 |
| %UD30 (%) | 134.8 (96.1-172.9) | 137.9 (106.0-172.9) | 0.833 |
| UD90 (Gy) | 141.2 (92.7-176.8) | 139.1 (86.6-193.7) | 0.673 |
| %UD90 (%) | 95.8 (63.4-149.2) | 94.2 (67.2-121.0) | 0.803 |
| R100 (mL) | 0.01 (0.00-1.00) | 0.03 (0.00-1.00) | 0.135 |
| BED (Gy2) | 197.7 (154.3-253.2) | 202.5 (151.4-246.2) | 0.635 |
PV: prostate volume at post-dosimetry, %D90: minimal percentage of the dose received by 90% of the prostate gland, D90: minimal does (Gy) received by 90% of the prostate gland, V100/V150: percentage of the prostate volume receiving 100% and 150% of the prescribed minimal peripheral dose, %UD30/UD30: minimal percentage of the dose and minimal dose (Gy) received by 30% of the urethra), %UD90/UD90: minimal percentage of the dose and minimal dose (Gy) received by 90% of the urethra, R100: rectal volume (mL) receiving 100% of the prescribed dose, and BED: biologically effective dose.